Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HXP124 for mild to moderate toenail onychomycosis
ACTRN12620000697987Phase 2Completed
- Sponsor
- Hexima
- Start
- Oct 2020
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of pezadeftide in onychomycosis and Distal Lateral Subungual Onychomycosis (DLSO) (6 cohorts), sponsored by Hexima. Primary endpoint: Safety and tolerability of topical HXP124 at Week 40. Started Oct 2020; status: completed.
02
Drugs
pezadeftide
03
Conditions
onychomycosisDistal Lateral Subungual Onychomycosis (DLSO)
Beyond the preview
Go deeper on ACTRN12620000697987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000697987.